Gillian Booth

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

Peter Hillmen, D. Cohen, Kim Cocks et al. · British Journal of Haematology · 2011 · 41 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

Julian D. Gillmore, Kim Cocks, Simon Gibbs et al. · Blood · 2009 · 16 citations

Medicine, Internal Medicine, Pharmacotherapy +6

Risk-adapted approaches to the management of clinical trials: guidance from the Department of Health (DH)/Medical Research Council(MRC)/Medicines and Healthcare Products Regulatory Agency (MHRA) Clinical Trials Working Group

Sarah Meredith, Martyn Ward, Gillian Booth et al. · Trials · 2011 · 15 citations · Full text

Pharmacy, Pharmaceutical Policy, Risk Management +16